CD34 and acute myeloid leukemia: Included in the latter is a retrospective European Society for Blood and Marrow Transplantation (EBMT) registry analysis, in which no correlation between CD34+ cell dose and post-HCT relapse or OS was found in adults receiving reduced intensity conditioning (RIC) allogeneic HCT for AML [27].